2 Very Strong looking Stocks Right Now-- 1. Snap Inc. (SNAP) 53.81+0.45 (+0.84%) S&P 500 4,098.66 -29.17(-0.71%) Dow 30 33,801.15 -259.51(-0.76%) Nasdaq 13,217.67 -85.97(-0.65%) Russell 2000 2,178.83 -32.04(-1.45%) 2. Roblox Corporation (RBLX) $75.65+0.66 (+0.88%) Zara Larsson Announces Exclusive Launch Party on Roblox, in Partnership with TEN Music Group and Epic Records Wed, May 19, 2021, 9:10 AM The Dance Party experience ties into the deluxe release of her recent album, Poster Girl Roblox(NYSE: RBLX), a global platform bringing millions of people together through shared experiences, and TEN Music Group and Epic Records announced today that pop-artist phenom Zara Larsson will host a Launch Party on the Roblox platform. The Dance Party themed experience will feature Larsson performing a set list that includes her new album title track "Poster Girl" Poster Girlis the third studio album by Swedish singer and songwriter Zara Larsson. ---> Coupang, Inc. (CPNG) 36.96-0.29 (-0.78%) As of 12:50PM EDT. Market open.
JSDA is the idea now. Jones Soda Co. (JSDA) Other OTC - Other OTC Delayed Price. Currency in USD 0.6065+0.0165 (+2.7966%) As of 12:48PM EDT. Market open.
Big Development In Stoner World-- This would be huge. Rite Aid 'keeping an eye on' carrying marijuana products - Hemp Industry Daily Rite Aid(NYSE:RAD)CEO Hayward Donigan is not ruling out carrying marijuana products at its stores one day, noting that the company is "keeping an eye on it,"Hemp Industry Dailyreported. Donigan made the comments at the recent Wall Street Journal Future of Everything Festival. Rite Aid has sold cannabidiol ("CBD") products since 2019. The executive added that the drug store chain is looking at selling more homeopathic products and all of its pharmacists have been re-certified as integrative pharmacy specialists. Rite Aid shares are down 4% to $19.28 in morning trading.
Colonial Pipeline CEO confirms $4.4M ransom payment to DarkSide otherwise known as Van. Colonial Pipeline CEO Joseph Blount tells The Wall Street Journalthat he authorized the $4.4M ransomware payment to the DarkSide ransomware-as-a-service group in order to quickly restore service to the pipeline. Bloomberg sources previously reported Colonial Pipeline had paid a nearly $5M ransom in cryptocurrency, but this is the first official confirmation from the company. The previous report said DarkSide had provided a decrypting tool, but the tool was so slow that Colonial Pipeline continued to use its own backups. The CEO says he didn't make the decision "lightly" and "wasn't comfortable seeing money go out the door to people like this," but the choice "was the right thing to do for the country." In its recent The State of Ransomware 2021 survey, security firm Sophos found that, on average, only 65% of encrypted data was restored after a target made a ransom payment. Only 8% of the targets were able to recover all of the encrypted data. The survey found that energy, gas, and oil companies were the most likely industries to pay a ransom due to the massive downtime costs and disruption. Related stocks: FireEye(FEYE-1.3%), CyberArk(CYBR-0.7%), CrowdStrike(CRWD+0.6%). Recent news: Last week, DarkSide said it was retreating after its servers were seized and its cryptocurrency account was drained by an outside party. Russia? Who Drained Darkside's account? That's a dinner guest!
" Hopefully a year...." Folks I don't see this ending well. I'm not coming back for no booster..... Top FDA officials are uncertain over how soon COVID-19 booster shots are needed The officials at the FDA remain uncertain over how quickly the fully vaccinated individuals for COVID-19 might need the booster shots. “So, hopefully, you know, it would be nice if it’ll turn out that it’ll be a year before anyone might need a booster,” Dr. Peter Marks was quoted by CNBC as saying at a virtual press conference with high school and middle school journalists. on Covid-19 vaccines. Dr. Marks is the director of the Center for Biologics Evaluation and Research (CBER), the FDA unit tasked with licensing over-the-counter and prescription drugs including vaccine products. “It could be more, it could be a little less but ... this is just something we’re gonna have to figure out as we go,” Marks said adding “but we still don’t know.” Acting FDA Commissioner Dr. Janet Woodcock echoed similar remarks pointing out that the regulators and scientists are not yet sure on the extent of immunity decline before vaccinated people become susceptible to the infection. “As far as variants go, we’re just going to have to determine that currently the immune response to these vaccines is being tested against all the variants to see how strong it is against each of the variants. And we just hope a variant doesn’t arise that can elude our vaccines,” Woodcock said. However, Dr. Rochelle Walensky director Centers for Disease Control and Prevention (CDC) has told CNBC last week that the U.S. was planning for a potential need of COVID-19 booster shots “just in case.” The views by FDA officials appear to diverge from some of the recent statements made by COVID-19 vaccine developers. Alfred Bourla, the CEO of Pfizer (PFE-1.0%) predicted in April that people might need a booster shot within six to twelve months after getting fully vaccinated. Pfizer partnered with BioNTech (BNTX-0.6%) to develop the first FDA-cleared COVID-19 vaccine. Some scientists including Dr. Tom Frieden, a former director of the U.S. CDC, recently questioned such a need citing lack of evidence.<-- GIVE THIS MAN A VOICE!!!!!!!
--KnowBe4 reports Q1 EPS 1c vs. (3c) last year --Jam City to become publicly traded company through merger with DPCM Capital 07:18 XPOA --Advanced Drainage reports Q4 EPS 23c, consensus 32c Advanced Drainage sees FY22 revenue $2.22B-$2.3B, consensus $2.09B 06:44 WMS Sees FY22 adjusted EBITDA $635M-$665M. Capital expenditures are expected to be $130M-$150M. Show Related Items >> --RingCentral recent selloff brings buying opportunity, says Mizuho 06:41 RNG Mizuho analyst Siti Panigrahi reiterates a Buy rating on RingCentral with a $400 price target after hosting meetings with management. With its partnerships "gaining meaningful traction," a large target market transitioning to the cloud, and its tech stack "meaningfully differentiated," RingCentral remains well positioned to drive "robust sustainable growth," Panigrahi tells investors in a research note. The analyst believes the current share price level presents a buying opportunity following the recent selloff. --Dick's Sporting price target raised to $93 ahead of Q1 report at Morgan Stanley 06:40 DKS Morgan --Baird starts 'significantly undervalued' VistaGen Therapeutics at Outperform 06:32 VTGN --Xebec Adsorption initiated with an Outperform at BMO Capital 05:00 XEBEF BMO Ca
Roth Capital sustainability analyst holds an analyst/industry conference call 04:55 ARRY, AZRE, BWEN, CSIQ, FSLR, GNRC, JKS, MAXN, SHLS, SOL Sustainability Analyst Shen, along with Founder & Executive Editor Reisman and VP Hauser of MetalMiner who will provide the latest outlook for the following metals: steel, copper, and aluminum on an Analyst/Industry conference call to be held on May 20 at 8 am. Analog Devices upped at Bernstein on tailwind from 'imminent' Maxim deal With the near- to medium-term view improved after yesterday's earnings, Bernstein upgrades Analog Devices(NASDAQ:ADI) from Market Perform to Outperform with a $185 price target. Analyst Stacy Rasgon notes the "continued solid demand 2H comm pickup, and a burgeoning EV narrative." Rasgon says the Maxim Integrated(NASDAQ:MXIM) deal looks "imminent," which could "markedly accelerate" cash return, "rapidly" returning ADI to $2-3B with leverage back to 1.5x targets. The combination could potentially drive over $4B in FCF by FY23, which will all be returned to shareholders. Analog Devices shares are up slightly pre-market to $154.36. Related: Yesterday, ADI reported FQ2 beats with upside sales guidance, driven byauto and industiral strength.
Sanofi's amcenestrant combo shows encouraging antitumor activity in early-stage breast cancer study In apooled analysisfrom Phase 1 AMEERA-1 trial, Sanofi's(NASDAQ:SNY)amcenestrant in combination with Pfizer's palbociclib (Ibrance) showed encouraging antitumor activity in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rateof 74%, with clinical benefit in 26/35 patients at 24 weeks in combination with palbociclib. Amcenestrant 200mg daily in combination with palbociclib demonstrated a favorable overall safety profile, with treatment related adverse events similar to those observed with monotherapy. A pivotal study (AMEERA-3) of amcenestrant versus physician’s choice in locally advanced or metastatic ER+ breast cancer is fully recruited with data readout expected in H2 2021. The early amcenestrant data support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer. The data will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.